Patients with thymoma/thymic carcinoma have been shown that those with high-PD-L1 expression (>50% of tumor cells) appeared to have responded better to pembrolizumab (an anti-PD-L1 reagent), compared to those with low-PD-L1 expression (21, 22). This evidence concerns the gene CD274 and thymoma.